Evogene Ltd. (NASDAQ/TASE: EVGN) is built around a platform-driven approach to computational life-sciences. Rather than operating purely as a traditional biotech R&D pipeline company, Evogene focuses on using data, deep biological insights, and artificial intelligence to digitally identify candidate solutions and guide their creation—spanning microbes, small molecules, and genetic components. ...Evogene Ltd. (NASDAQ/TASE: EVGN) is built around a platform-driven approach to computational life-sciences. Rather than operating purely as a traditional biotech R&D pipeline company, Evogene focuses on using data, deep biological insights, and artificial intelligence to digitally identify candidate solutions and guide their creation—spanning microbes, small molecules, and genetic components. This “computational predictive biology” orientation is intended to reduce uncertainty and shorten the path from target identification to development concepts.
Business-wise, Evogene’s operations are commonly described through three main divisions. In Agriculture, the company works on product and technology themes such as seed traits, agricultural chemicals, and biological products intended to improve plant performance. Efforts can cover major crops (e.g., corn, soybean, wheat, rice, and cotton) and involve partnering and licensing relationships with large agribusinesses. In Human Health, Evogene emphasizes discovering and developing microbiome-based treatments, including potential applications in immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. In Industrial Applications, Evogene has also been associated with improving castor bean seeds for downstream industrial uses.
From a product/technology perspective, Evogene has highlighted distinct AI “tech-engines” and a core platform model (including a ChemPass AI platform concept in public descriptions). The overall strategy is to combine proprietary computational methods with life-science domain knowledge to generate and prioritize candidates, which can then be progressed through partner development or internal programs depending on the collaboration structure.
In terms of cost and BOM considerations, the company’s model typically relies more heavily on software/compute, specialized scientific expertise, and platform development than on large-scale wet-lab manufacturing. However, like most computational drug/discovery and ag-biotech efforts, project commercialization still requires downstream R&D spend (experiments, validation, regulatory/production steps for specific indications). Financially, the provided dataset indicates ongoing operating investment and negative profitability metrics on a trailing-twelve-month basis, which is common for early-to-mid-stage development-focused biopharma and life-sciences technology firms.
Key people include Ofer Haviv (President & CEO) and board leadership such as Nir Nimrodi (Chairperson), with founders identified as Dr. Hagai Karchi and Dr. Rafi Meissner in the provided information. Looking ahead, Evogene’s “wish” and market rationale is generally aligned with converting computational discoveries into partnered products and advancing platform capabilities (AI engines and predictive performance) that improve success rates and enable scalable collaboration with major pharmaceutical and agricultural-chemical stakeholders.
Operator: Welcome to Evogene's Second Quarter 2026 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded on August 18, 2026. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Evogene Ltd. may, from time to time, make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA and other securities laws as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intend and potential or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market size and milestones, pipeline as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expected or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah and Iran and other regional terrorist groups supported by Iran and any destabilization in Israel, neighboring territories or the Middle East region and those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnished with the Israel Securities authorities and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or publicly release the results of any revisions to any statements that may be made to reflect future events or development or changes in expectations, estimates, projections and assumptions. The information contained herein …
